Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Gary Mohilner who wrote (5565)	5/4/2016 8:55:14 PM
From: Gary Mohilner	Respond to of 5665

investorvillage.com The above link is from JV over on IV and lists all the abstracts he'd found for products IMGN is involved in at ASCO. He actually found more and posted them as well. I'm pointing this out because I also wanted to indicate I bought some July calls as well, as they fall well after ASCO and ought to benefit from what's being presented there. Certainly, not every abstract will be a major positive, but I like the odds of a fair number of the presentations being positive and frankly I bought $7's for less money then I would have paid for $10's about a month ago. I cannot say with any certainty what price ASCO and a new CEO may bring, but I strongly believe $10 to $15 could be in the cards once some questions about trials, and management are established. While I'd hope our new CEO would address shareholders before the July expiration, I don't know that in fact it will happen, as the quarterly report won't occur prior to that date. If I'm correct about what the price could be by expiration call, I most definitely will be adding some shares to my holdings. Gary